BIOVEX TREATS FIRST PATIENTS IN MALIGNANT MELANOMA STUDY

BioVex has announced today that the first patients in its Phase II clinical trials of OncoVEXGMCSF in malignant melanoma and in head and neck cancer had received their initial doses of the therapeutic treatment.

The melanoma trial is a 50 patient multi-center study. The primary endpoint of the study is tumor response rate with secondary endpoints including time to disease progression and median survival time.

The head and neck cancer trial is a 16-patient open-label study in combination with chemoradiotherapy. The first patient in this trial has recently completed the seven week dosing regime. The endpoint of the trial is to assess the safety of OncoVEXGMCSF combined with chemoradiotherapy, and the potential of OncoVEX as neoadjuvant therapy in the treatment of head and neck cancer.